• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Monday's Pre-Market Session

    3/6/23 8:06:18 AM ET
    $ACRS
    $ADAP
    $ARMP
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ACRS alert in real time by email

    Gainers

    • Unicycive Therapeutics (NASDAQ:UNCY) shares increased by 114.3% to $1.05 during Monday's pre-market session. The company's market cap stands at $15.8 million.
    • BridgeBio Pharma (NASDAQ:BBIO) stock moved upwards by 56.39% to $17.0. The market value of their outstanding shares is at $2.5 billion.
    • vTv Therapeutics (NASDAQ:VTVT) stock increased by 48.51% to $1.2. The company's market cap stands at $97.7 million.
    • Kala Pharmaceuticals (NASDAQ:KALA) shares increased by 27.46% to $21.35. The company's market cap stands at $39.9 million. The company's, Q4 earnings came out yesterday.
    • TCR2 Therapeutics (NASDAQ:TCRR) shares rose 25.61% to $1.52. The market value of their outstanding shares is at $58.7 million.
    • Armata Pharmaceuticals (AMEX:ARMP) shares increased by 16.66% to $3.22. The market value of their outstanding shares is at $116.3 million.

    Losers

    • Aclaris Therapeutics (NASDAQ:ACRS) shares decreased by 36.5% to $8.11 during Monday's pre-market session. The company's market cap stands at $540.8 million.
    • Esperion Therapeutics (NASDAQ:ESPR) stock decreased by 33.76% to $4.2. The market value of their outstanding shares is at $321.6 million.
    • Adaptimmune Therapeutics (NASDAQ:ADAP) stock decreased by 26.14% to $1.3. The company's market cap stands at $212.9 million. The company's, Q4 earnings came out today.
    • Rubius Therapeutics (NASDAQ:RUBY) shares declined by 19.94% to $0.1. The company's market cap stands at $9.0 million.
    • Sesen Bio (NASDAQ:SESN) shares declined by 13.25% to $0.54. The company's market cap stands at $108.4 million. As per the news, the Q4 earnings report came out 4 days ago.
    • Etao International Co (NASDAQ:ETAO) stock fell 12.84% to $1.97. The company's market cap stands at $208.2 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ACRS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACRS
    $ADAP
    $ARMP
    $BBIO

    CompanyDatePrice TargetRatingAnalyst
    BridgeBio Pharma Inc.
    $BBIO
    1/28/2026$157.00Overweight
    Barclays
    vTv Therapeutics Inc.
    $VTVT
    1/23/2026$58.00Buy
    Roth Capital
    BridgeBio Pharma Inc.
    $BBIO
    1/6/2026$96.00Overweight
    Morgan Stanley
    vTv Therapeutics Inc.
    $VTVT
    1/5/2026$67.00Buy
    TD Cowen
    BridgeBio Pharma Inc.
    $BBIO
    12/11/2025$94.00Outperform
    Bernstein
    Esperion Therapeutics Inc.
    $ESPR
    11/25/2025$9.00Overweight
    Piper Sandler
    vTv Therapeutics Inc.
    $VTVT
    11/19/2025$40.00Buy
    BTIG Research
    KALA BIO Inc.
    $KALA
    9/30/2025$1.50Outperform → Neutral
    Mizuho
    More analyst ratings

    $ACRS
    $ADAP
    $ARMP
    $BBIO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Director Valantine Hannah bought $24,948 worth of shares (1,752 units at $14.24), increasing direct ownership by 114% to 3,294 units (SEC Form 4)

    4/A - BridgeBio Pharma, Inc. (0001743881) (Issuer)

    6/30/25 5:49:25 PM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: Director Valantine Hannah bought $30,028 worth of shares (2,338 units at $12.84) (SEC Form 4)

    4/A - BridgeBio Pharma, Inc. (0001743881) (Issuer)

    6/30/25 5:46:18 PM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Baker Bros. Advisors Lp bought $2,000,000 worth of shares (310,559 units at $6.44) (SEC Form 4)

    4 - KALA BIO, Inc. (0001479419) (Issuer)

    12/31/24 4:00:18 PM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRS
    $ADAP
    $ARMP
    $BBIO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Aclaris Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

    - Positive Interim Results of Phase 1a Single (SAD) and Multiple Ascending Dose (MAD) Trial of Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052 Support Rapid Clinical Advancement; Complete Top Line Results Expected in the Second Quarter of 2026 - - Phase 1b Proof-of-Concept Trials of ATI-052 in Atopic Dermatitis (AD) and Asthma Underway; Top Line Results from Both Trials Anticipated in the Second Half of 2026 - - Investigational New Drug (IND) Application for Lead ITK Inhibitor Candidate ATI-9494 Expected in the SecondHalf of 2026 - - ATI-2138, Aclaris' Investigational Inhibitor of ITK and JAK3, Demonstrated Potential Best-in-Class Hair Regrowth in Murine Alopecia Model -  WAYNE, Pa., Feb. 26,

    2/26/26 6:58:00 AM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BridgeBio Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial Updates

    $154.2 million in total fourth quarter revenues, net, and $502.1 million in full year revenues, net, primarily comprised of net product revenue of $146.0 million and $362.4 million, respectivelyBridgeBio reported three positive Phase 3 trial readouts in just over three months, a demonstration of its unique model for sustainable drug development as described in a recent peer-reviewed manuscriptAttruby continues to demonstrate clinical differentiation as a first-choice therapy in ATTR-CM with the greatest TTR stabilization on the market (≥90%) and the most rapid benefit on clinical outcomes observed within 1 month, with 7,804 unique patient prescriptions written by 1,856 unique prescribers as

    2/24/26 4:01:00 PM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Esperion to Report Fourth Quarter and Full Year 2025 Financial Results on March 10

    ANN ARBOR, Mich., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced it will report fourth quarter and full year 2025 financial results before the market opens on Tuesday, March 10, 2026. Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financial results and provide business updates. A live audio webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after completion of the call and will be archived on the Company's website for approximately 90 days. Esperion TherapeuticsEsperion Therapeutics, Inc. is a commercial-stage biopharmac

    2/24/26 8:00:00 AM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRS
    $ADAP
    $ARMP
    $BBIO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for ATTRUBY issued to BRIDGEBIO PHARMA INC

    Submission status for BRIDGEBIO PHARMA INC's drug ATTRUBY (ORIG-1) with active ingredient ACORAMIDIS has changed to 'Approval' on 11/22/2024. Application Category: NDA, Application Number: 216540, Application Classification: Type 1 - New Molecular Entity

    11/25/24 8:41:11 AM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for NEXLIZET issued to ESPERION THERAPS INC

    Submission status for ESPERION THERAPS INC's drug NEXLIZET (SUPPL-16) with active ingredient BEMPEDOIC ACID; EZETIMIBE has changed to 'Approval' on 03/22/2024. Application Category: NDA, Application Number: 211617, Application Classification: Efficacy

    3/25/24 4:41:30 AM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for NEXLIZET issued to ESPERION THERAPS INC

    Submission status for ESPERION THERAPS INC's drug NEXLIZET (SUPPL-17) with active ingredient BEMPEDOIC ACID; EZETIMIBE has changed to 'Approval' on 03/22/2024. Application Category: NDA, Application Number: 211617, Application Classification: Efficacy

    3/25/24 4:41:37 AM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRS
    $ADAP
    $ARMP
    $BBIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on BridgeBio Pharma with a new price target

    Barclays initiated coverage of BridgeBio Pharma with a rating of Overweight and set a new price target of $157.00

    1/28/26 7:16:00 AM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Roth Capital initiated coverage on vTv Therapeutics with a new price target

    Roth Capital initiated coverage of vTv Therapeutics with a rating of Buy and set a new price target of $58.00

    1/23/26 8:21:38 AM ET
    $VTVT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Morgan Stanley initiated coverage on BridgeBio Pharma with a new price target

    Morgan Stanley initiated coverage of BridgeBio Pharma with a rating of Overweight and set a new price target of $96.00

    1/6/26 8:54:42 AM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRS
    $ADAP
    $ARMP
    $BBIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Accounting Officer Apuli Maricel sold $132,000 worth of shares (2,000 units at $66.00), decreasing direct ownership by 2% to 121,945 units (SEC Form 4)

    4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)

    2/27/26 4:11:15 PM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Kumar Neil sold $2,002,717 worth of shares (28,053 units at $71.39), decreasing direct ownership by 11% to 234,451 units (SEC Form 4)

    4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)

    2/23/26 4:32:04 PM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Kumar Neil converted options into 64,698 shares and covered exercise/tax liability with 30,970 shares, increasing direct ownership by 15% to 262,504 units (SEC Form 4)

    4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)

    2/18/26 6:41:47 PM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRS
    $ADAP
    $ARMP
    $BBIO
    SEC Filings

    View All

    SEC Form 10-K filed by Aclaris Therapeutics Inc.

    10-K - Aclaris Therapeutics, Inc. (0001557746) (Filer)

    2/26/26 4:31:23 PM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    vTv Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - vTv Therapeutics Inc. (0001641489) (Filer)

    2/26/26 7:51:23 AM ET
    $VTVT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aclaris Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Aclaris Therapeutics, Inc. (0001557746) (Filer)

    2/26/26 7:15:27 AM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRS
    $ADAP
    $ARMP
    $BBIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Aclaris Therapeutics Inc.

    SC 13G - Aclaris Therapeutics, Inc. (0001557746) (Subject)

    11/25/24 11:02:19 AM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Aclaris Therapeutics Inc.

    SC 13G - Aclaris Therapeutics, Inc. (0001557746) (Subject)

    11/22/24 4:00:23 PM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Aclaris Therapeutics Inc.

    SC 13G - Aclaris Therapeutics, Inc. (0001557746) (Subject)

    11/21/24 4:51:50 PM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRS
    $ADAP
    $ARMP
    $BBIO
    Leadership Updates

    Live Leadership Updates

    View All

    Esperion Appoints Industry Veteran John Harlow as Chief Commercial Officer

    – Brings Extensive Executive Leadership Driving Commercial Strategies That Enhance Sales and Marketing Performance – ANN ARBOR, Mich., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced the appointment of John Harlow as the Company's Chief Commercial Officer, effective November 17, 2025. Mr. Harlow will join Esperion's Executive Leadership Team and will report directly to Sheldon Koenig, President and CEO of Esperion.    "We are thrilled to welcome John as our Chief Commercial Officer at such a pivotal time in Esperion's growth, as we continue to expand adoption of our products in the U.S. and increase our global footprint," said Koenig. "John's deep domain expertise

    11/4/25 8:00:00 AM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    vTv Therapeutics Announces New Appointments to its Scientific Advisory Board

    HIGH POINT, N.C., Oct. 09, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, today announced the appointment of Alfonso Galderisi, MD, PhD, Mark Evans, MD, Chantal Mathieu, MD, PhD, and Klara Klein, MD, PhD, to its Scientific Advisory Board (SAB). The SAB, composed of internationally recognized leaders in endocrinology, diabetes research, clinical trial design, and regulatory science, will continue providing strategic guidance on the development of cadisegliatin, which is currently being investigated in Phase 3 clinical trials as an oral adjunctive therapy to insulin for the treatment of type 1

    10/9/25 8:00:00 AM ET
    $VTVT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    KALA BIO Appoints Todd Bazemore as President, Chief Executive Officer and Director

    ARLINGTON, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that Todd Bazemore has been named President and Chief Executive Officer (CEO) of KALA BIO and appointed to the Board of Directors. Mr. Bazemore has served as KALA's interim CEO since February 2025 and previously served as KALA's President and Chief Operating Officer (COO). "Throughout his tenure, including as interim CEO and President and COO, Todd's leadership has been instrumental in driving KALA's clinical progress and str

    9/2/25 8:00:00 AM ET
    $KALA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRS
    $ADAP
    $ARMP
    $BBIO
    Financials

    Live finance-specific insights

    View All

    Aclaris Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

    - Positive Interim Results of Phase 1a Single (SAD) and Multiple Ascending Dose (MAD) Trial of Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052 Support Rapid Clinical Advancement; Complete Top Line Results Expected in the Second Quarter of 2026 - - Phase 1b Proof-of-Concept Trials of ATI-052 in Atopic Dermatitis (AD) and Asthma Underway; Top Line Results from Both Trials Anticipated in the Second Half of 2026 - - Investigational New Drug (IND) Application for Lead ITK Inhibitor Candidate ATI-9494 Expected in the SecondHalf of 2026 - - ATI-2138, Aclaris' Investigational Inhibitor of ITK and JAK3, Demonstrated Potential Best-in-Class Hair Regrowth in Murine Alopecia Model -  WAYNE, Pa., Feb. 26,

    2/26/26 6:58:00 AM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BridgeBio Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial Updates

    $154.2 million in total fourth quarter revenues, net, and $502.1 million in full year revenues, net, primarily comprised of net product revenue of $146.0 million and $362.4 million, respectivelyBridgeBio reported three positive Phase 3 trial readouts in just over three months, a demonstration of its unique model for sustainable drug development as described in a recent peer-reviewed manuscriptAttruby continues to demonstrate clinical differentiation as a first-choice therapy in ATTR-CM with the greatest TTR stabilization on the market (≥90%) and the most rapid benefit on clinical outcomes observed within 1 month, with 7,804 unique patient prescriptions written by 1,856 unique prescribers as

    2/24/26 4:01:00 PM ET
    $BBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Esperion to Report Fourth Quarter and Full Year 2025 Financial Results on March 10

    ANN ARBOR, Mich., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced it will report fourth quarter and full year 2025 financial results before the market opens on Tuesday, March 10, 2026. Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financial results and provide business updates. A live audio webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after completion of the call and will be archived on the Company's website for approximately 90 days. Esperion TherapeuticsEsperion Therapeutics, Inc. is a commercial-stage biopharmac

    2/24/26 8:00:00 AM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care